Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Swedish Orphan Biovitrum ABSWOBY 67 Operating Cash Flow per Share is $1.20 as of Jun. 2026. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $18.74 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 760 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 63.42% on this metric.
Swedish Orphan Biovitrum AB's operating cash flow per share for the
three
months ended in Jun. 2026 was $0.29.
Swedish Orphan Biovitrum AB's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $1.20.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Swedish Orphan Biovitrum AB was 15.90% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 18.90% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 8.10% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 30.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's Operating Cash Flow per Share or its related term are showing as below:
SWOBY'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -91.8 Med: 20.5 Max: 113.2
Current: 18.9
During the past 13 years, Swedish Orphan Biovitrum AB's highest 3-Year average Operating Cash Flow per Share Growth Rate was 113.20% per year. The lowest was -91.80% per year. And the median was 20.50% per year.
SWOBY's 3-Year OCF Growth Rate is ranked better than 63.42% of 760
companies
in the Drug Manufacturers industry
Industry Median: 7.25
vs SWOBY: 18.90
Swedish Orphan Biovitrum AB Operating Cash Flow per Share Related Terms
Swedish Orphan Biovitrum AB Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Swedish Orphan Biovitrum AB's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB Operating Cash Flow per Share Chart
SWOBY vs ZTS: Operating Cash Flow per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $1.20 mean?
Swedish Orphan Biovitrum AB (SWOBY) has a Operating Cash Flow per Share of $1.20 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Swedish Orphan Biovitrum AB and its competitors. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #278 out of 760 companies in the Drug Manufacturers industry, placing it in the top 36.6%.
Is Swedish Orphan Biovitrum AB's Operating Cash Flow per Share too high?
Swedish Orphan Biovitrum AB's current Operating Cash Flow per Share is $1.20. The Drug Manufacturers industry median Operating Cash Flow per Share is 7.25. Swedish Orphan Biovitrum AB's value of $1.20 is 83.4% below this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #278 out of 760 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Operating Cash Flow per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #278 out of 760 companies for Operating Cash Flow per Share. This puts Swedish Orphan Biovitrum AB in the upper half of its industry. The industry median Operating Cash Flow per Share is 7.25. Swedish Orphan Biovitrum AB's value of $1.20 is 83.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Drug Manufacturers company?
The median Operating Cash Flow per Share among Drug Manufacturers companies is 7.25, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Operating Cash Flow per Share of $1.20 is 83.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Operating Cash Flow per Share is 7.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Operating Cash Flow per Share is $1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Modestly Overvalued. The stock's GF Value™ is $18.74, compared to a current price of $24.29 — trading 29.6% above its estimated fair value. The current Operating Cash Flow per Share is $1.20 and 83.4% below the Drug Manufacturers industry median of 7.25. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Operating Cash Flow per Share is $1.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $24.29 is trading 29.6% above its estimated GF Value™ of $18.74.
GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.
Key valuation signals for SWOBY:
Operating Cash Flow per Share: $1.20
GF Value™: $18.74 vs. price of $24.29 (29.6% above fair value)
Industry Position: 83.4% below the Drug Manufacturers median (#278 of 760)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
